肝胆相照论坛

标题: 肝细胞癌的立体定向放射疗法(SBRT) [打印本页]

作者: StephenW    时间: 2021-2-12 20:35     标题: 肝细胞癌的立体定向放射疗法(SBRT)

Stereotactic Body Radiation Therapy (SBRT) in Hepatocellular Carcinoma

    Horatio R. Thomas & Mary Feng

Current Hepatology Reports volume 20, pages12–22(2021)Cite this article

    110 Accesses

    Metrics details

Abstract
Purpose of Review

Hepatocellular carcinoma (HCC) is a rising cause of mortality and morbidity, and although surgical resection is the preferred curative local therapy, < 30% of patients are candidates at diagnosis. This review discusses SBRT as an option in a variety of clinical scenarios.
Recent Findings

Multiple retrospective and prospective studies demonstrate that stereotactic body radiation therapy (SBRT) is an effective bridge for transplant candidates and local therapy for patients with inoperable early-, intermediate-, or advanced-stage disease. SBRT is associated with excellent local control, and it is well-tolerated despite study cohorts enriched with patients who failed prior therapies and had poor baseline liver function.
Summary

Additional randomized control trials are needed to determine the ideal treatment regimen and patient selection for SBRT.
作者: StephenW    时间: 2021-2-12 20:35

肝细胞癌的立体定向放射疗法(SBRT)

    Horatio R.托马斯和冯丽

《当前肝病学报告》第20卷,第12–22(2021)页,引用本文

    110次访问

    指标详细信息

抽象的
审查目的

肝细胞癌(HCC)是导致死亡率和发病率上升的原因,尽管外科手术切除是首选的治疗性局部疗法,但仍有不到30%的患者可以诊断。这篇评论讨论了SBRT作为各种临床方案中的一种选择。
最近的发现

多项回顾性和前瞻性研究表明,立体定向放射疗法(SBRT)是可移植的候选药物和对无法手术的早期,中期或晚期疾病患者进行局部治疗的有效桥梁。 SBRT与出色的局部控制有关,尽管研究人群中有大量既往治疗失败且基线肝功能较差的患者,但SBRT的耐受性良好。
概括

需要其他随机对照试验来确定SBRT的理想治疗方案和患者选择。
作者: StephenW    时间: 2021-2-12 20:36

https://link.springer.com/articl ... c_springer_20210212




欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) Powered by Discuz! X1.5